# Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

> **NCT03580694** · PHASE1 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 17 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** REGN4659
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT03580694
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-27
- **Primary completion:** 2019-12-04
- **Final completion:** 2019-12-04
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Program reprioritization
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03580694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03580694, "Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03580694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*